Recent experiments in mouse models of lung cancer have shown that (89) targeting USP7 with USP7 inhibitor P5091 upregulates the expression of PD-L1 protein in Lewis tumor cells and blocks PD-1, leading to an effective anti-tumor response in lung cancer. Here, RPL17 is linked to neoplasm.